塔奎妥单抗(Talquetamab) - 药物靶点：CD3 x GPRC5D_在研适应症：多发性骨髓瘤，外周干细胞移植，难治性多发性骨髓瘤_专利_临床

概要

基本信息

药物类型

双特异性T细胞结合器

别名

DuoBody、TALQUETAMAB-TGVS、JNJ 64407564

+ [4]

靶点

CD3 x GPRC5D

作用机制

CD3刺激剂(T细胞表面糖蛋白CD3复合体刺激剂)、GPRC5D抑制剂(G蛋白偶联受体家族C组5成员D抑制剂)、ADCC(抗体依赖的细胞毒作用)

治疗领域

肿瘤免疫系统疾病心血管疾病+ [2]

在研适应症

多发性骨髓瘤外周干细胞移植难治性多发性骨髓瘤+ [2]

非在研适应症-

原研机构

Janssen Pharmaceuticals, Inc.

在研机构

Janssen Research & Development LLC

强生（中国）投资有限公司

Janssen Pharmaceutica NV

+ [6]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2023-08-09),

多发性骨髓瘤

最高研发阶段(中国)申请上市

特殊审评突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先药物（PRIME） (欧盟)、优先审评 (中国)、突破性疗法 (中国)、孤儿药 (韩国)、附条件批准 (欧盟)

登录后查看时间轴

结构/序列

Sequence Code 10086313H

来源: *****

Sequence Code 10086327L

来源: *****

Sequence Code 453116282H

来源: *****

Sequence Code 525754800L

来源: *****

关联

31

项与塔奎妥单抗相关的临床试验

NCT06461988

/ Not yet recruiting临床2期IIT

An Open-Label, Non-Randomized, Multicenter, Phase II Study to Study the Efficacy of Talquetamab (JNJ-64407564) and Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma (OPTIMMAL)

Multiple myeloma (MM) is a heterogenous plasma cell malignancy characterized by clonal proliferation of plasma cells and organ damage. Autologous transplantation with high dose chemotherapy is the standard of care in frontline treatment of eligible patients with MM.

开始日期2025-11-01

申办/合作机构

Stanford University

[+1]

NCT06550895

/ Recruiting临床2期

A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).

开始日期2024-09-16

申办/合作机构

Janssen Research & Development LLC

NCT06500884

/ Recruiting临床2期

A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicity

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related distorted taste (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related distorted taste.

开始日期2024-08-26

申办/合作机构

Janssen Research & Development LLC

100 项与塔奎妥单抗相关的临床结果

登录后查看更多信息

100 项与塔奎妥单抗相关的转化医学

登录后查看更多信息

100 项与塔奎妥单抗相关的专利（医药）

登录后查看更多信息

51

项与塔奎妥单抗相关的文献（医药）

2025-01-09·NEW ENGLAND JOURNAL OF MEDICINE

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma

Article

作者: Krevvata, Maria ; Min, Chang-Ki ; Morillo, Daniel ; Ocio, Enrique M ; Vanak, Jill ; Quijano Cardé, Natalia A ; Avivi, Irit ; Cohen, Yael C ; Di Scala, Lilla ; Mateos, María-Victoria ; Banerjee, Arnob ; Yoon, Sung-Soo ; Rodríguez-Otero, Paula ; Kim, Kihyun ; Chu, Michael P ; Oriol, Albert ; Hilder, Brandi ; Magen, Hila ; Kumar, Ashwini ; Scott, Emma ; Sebag, Michael ; Gatt, Moshe ; Peterson, Michelle R

BACKGROUND:

Talquetamab (anti-G protein-coupled receptor family C group 5 member D) and teclistamab (anti-B-cell maturation antigen) are bispecific antibodies that activate T cells by targeting CD3 and that have been approved for the treatment of triple-class-exposed relapsed or refractory multiple myeloma.

METHODS:

We conducted a phase 1b-2 study of talquetamab plus teclistamab in patients with relapsed or refractory multiple myeloma. In phase 1, we investigated five dose levels in a dose-escalation study. Talquetamab at a dose of 0.8 mg per kilogram of body weight plus teclistamab at a dose of 3.0 mg per kilogram every other week was selected as the recommended phase 2 regimen. The primary objective was to evaluate adverse events and dose-limiting toxic effects.

RESULTS:

A total of 94 patients received treatment, with the recommended phase 2 regimen used in 44. The median follow-up was 20.3 months. Three patients had dose-limiting toxic effects (including grade 4 thrombocytopenia in 1 patient with the recommended phase 2 regimen). Across all dose levels, the most common adverse events were cytokine release syndrome, neutropenia, taste changes, and nonrash skin events. Grade 3 or 4 adverse events, most commonly hematologic events, occurred in 96% of the patients. Grade 3 or 4 infections occurred in 64% of the patients. With the recommended phase 2 regimen, a response occurred in 80% of the patients (including in 61% of those with extramedullary disease); across all dose levels, a response occurred in 78%. The likelihood of patients continuing in response at 18 months was 86% with the recommended phase 2 regimen (82% among those with extramedullary disease) and 77% across all dose levels.

CONCLUSIONS:

The incidence of grade 3 or 4 infections with talquetamab plus teclistamab was higher than has been observed with either therapy alone. A response was observed in a high percentage of patients across all dose levels, with durable responses with the recommended phase 2 regimen. (Funded by Janssen Research and Development; RedirecTT-1 ClinicalTrials.gov number, NCT04586426.).

2025-01-01·BLOOD REVIEWS

Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection

Review

作者: Shouse, Geoffrey

Bispecific antibody therapy has revolutionized the treatment of hematologic malignancies. There are currently 7 FDA approved products with 4 different targets covering 5 indications in 4 diseases. Products include blinatumomab targeting B-cell ALL in MRD detectable first remission and in relapsed and/or refractory disease, elranatamab and teclistamab targeting BCMA in relapsed/refractory multiple myeloma, talquetamab targeting GPCR5D in multiple myeloma, and mosunetuzumab, epcoritamab and glofitamab which all target CD20 in follicular lymphoma, both follicular and large B cell lymphoma, or large B cell lymphoma alone, respectively. Each product utilizes the strategy of T-cell redirection by binding CD3 on the effector cell to target immune cells toward a tumor associated antigen. There are overlapping toxicities related to activation of the immune system and inflammation. The role of these agents in earlier lines of therapy and in novel combinations are under heavy investigation and their full utility and benefit in the treatment of hematologic malignancies is yet to be fully realized.

2024-12-31·mAbs

Antibodies to watch in 2024

Article

作者: Kaplon, Hélène ; Crescioli, Silvia ; Wang, Lin ; Reichert, Janice M. ; Visweswaraiah, Jyothsna ; Chenoweth, Alicia

The 'Antibodies to Watch' article series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval in any country. In this installment, we discuss key details for 16 antibody therapeutics granted a first approval in 2023, as of November 17 (lecanemab (Leqembi), rozanolixizumab (RYSTIGGO), pozelimab (VEOPOZ), mirikizumab (Omvoh), talquetamab (Talvey), elranatamab (Elrexfio), epcoritamab (EPKINLY), glofitamab (COLUMVI), retifanlimab (Zynyz), concizumab (Alhemo), lebrikizumab (EBGLYSS), tafolecimab (SINTBILO), narlumosbart (Jinlitai), zuberitamab (Enrexib), adebrelimab (Arelili), and divozilimab (Ivlizi)). We briefly review 26 product candidates for which marketing applications are under consideration in at least one country or region, and 23 investigational antibody therapeutics that are forecast to enter regulatory review by the end of 2024 based on company disclosures. These nearly 50 product candidates include numerous innovative bispecific antibodies, such as odronextamab, ivonescimab, linvoseltamab, zenocutuzumab, and erfonrilimab, and antibody-drug conjugates, such as trastuzumab botidotin, patritumab deruxtecan, datopotamab deruxtecan, and MRG002, as well as a mixture of two immunocytokines (bifikafusp alfa and onfekafusp alfa). We also discuss clinical phase transition and overall approval success rates for antibody therapeutics, which are crucial to the biopharmaceutical industry because these rates inform decisions about resource allocation. Our analyses indicate that these molecules have approval success rates in the range of 14-32%, with higher rates associated with antibodies developed for non-cancer indications. Overall, our data suggest that antibody therapeutic development efforts by the biopharmaceutical industry are robust and increasingly successful.

354

项与塔奎妥单抗相关的新闻（医药）

2025-01-25

·Antibody Research

抗体设计的艺术：罗氏跟维立志博CD3/GPRC5D之别

▎追溯 CD3抗体的设计，在一定角度上，它是一种工程设计的艺术。那么，今天来说一下，罗氏旗下和维立志博的CD3/GPRC5D多抗设计区别，同时也可以窥见，现如今创新药领域国内人才济济，抗体设计水平，在这十年间发生了质的改变，中国年轻一代的研发人员，正在撑起中国药物研发的未来。罗氏和维立志博都开发了CD3/GPRC5D双抗，均采用2+1的模式。而罗氏的思路采用的是高亲和力CD3抗体，这一点有点反常规，而维立志博利用了空间位阻进一步降低了CD3结合能力，提高安全性窗口。通过临床前的数据对比也可以看出Forimtamig具有较强的非特异性激活能力，一定程度上可能会有非特异性激活的毒性副作用。维立志博LBL-034采用的结构，GPRC5D FAB会对下方的CD3 scFv产生一定的空间位阻，减弱了CD3的结合能力。从下图E中可以看出，CD3的结合是非常微弱的，Jurkat细胞天然表达CD3。Benchmark是强生talquetamab。我们从另一个角度来思考，CD3抗体的结合，即便微弱，也足够引起T细胞内部信号通路的激活。同时，2+1模式有其优势，相比于1+1模式，在CD3抗体相当的条件，能够实现更高的TAA依赖性激活和杀伤。强生和维立志博CD3来源于SP34。维志立博在招股书中也展示了一些总结比较。我们再通过临床数据看一下几者的差异，从临床给药爬坡来看，强生的Talquetamab和维立志博的LBL-034 ug/kg给药，到了罗氏Forimtamig就成了ug/人给药了，其中LBL-034爬坡剂量窗口更高，显然Forimtamig最差。安全性问题，Forimtamig会发生3-4级CRS，LBL-034和Talquetamab均为1-2级。根据临床前数据来看这样的结果也是可以想见的。疗效方面，Talquetamab在400ug/kg，800ug/kg两个剂量下CR分别为35%和33%，Forimtamig在IV和SC两种给药方式下CR分别为34.7%和25.5%。两者大体相似，非头对头数据仅供参考。 LBL-034疗效还在早期，在高剂量组展现了优异的客观缓解率。以此，我们做下总结，CD3抗体的设计，目前大多数采用的是低亲和力，TAA依赖性激活。维立志博和强生均采用的SP34改造抗体，罗氏Forimtamig可能衍生于SP34（个人猜测未考证，仅从CDR判断），但CDR变动较大。非TAA依赖性激活太强容易引起安全性问题。维立志博采用空间位阻，进一步提高了治疗窗口。维立志博的抗体设计思路，在一定程度上为后续CD3多抗的开发提供了很好的思路。当然能否很好的应用于实体瘤还需要验证。后续在此基础上开发CD3/41BB多抗也是一种很好的平台，当然41BB未必需要隐藏，对于外周T细胞结合，或许一定程度上有利于将T细胞引流至肿瘤微环境，维立志博旗下41BB抗体的安全性在PDL1/41BB管线上已经得到很好的体现。多发性骨髓瘤本身存在异质性问题，以目前的数据来看，虽然GPRC5D广泛表达，但可能还是需要联用BCMA等靶点，以此来提高CR，所以目前强生着力在开发CD3/GPRC5D联用CD3/BCMA，RP2D剂量下CR为52%，旗下也开发了CD3/GPRC5D/BCMA三抗。欢迎加入我的知识星球，可提供专业的免费咨询，同时可以获得Antibody Research生物药随谈回放视频。公众号已经建立读者实名讨论微信群，可以添加微信（zhuisu2210）后进群，添加时请主动注明姓名、企业、职位。

2025-01-22

·医药魔方

强生2024年财报出炉！达雷妥尤单抗116亿美元，传奇CAR-T同比增长92.7%

1月22日，强生公布了2024年业绩，全年总营收888.21亿美元，同比增长4.3%。强生旗下两大核心业务板块——创新制药和医疗科技，分别实现了569.64亿美元（+4.0%）以及318.57亿美元（+4.8%）的收入。强生的创新制药业务主要聚焦肿瘤、自身免疫、神经科学、感染、肺动脉高压、心血管及代谢这几大关键领域。其中，肿瘤和自免对业绩的贡献最为突出，前者在2024全年取得了207.81亿美元的收入，同比增长17.7%；后者收入178.28亿美元，同比下降1.2%。此外，肺动脉高压产品收入42.82亿美元，同比增长12.3%，同样成为了整体业务不断发展的强劲推动力。 2024年强生肿瘤业务的增长主要归功于Darzalex（达雷妥尤单抗）、Erleada（阿帕他胺）、Carvykti（西达基奥仑赛）、Tecvayli（特立妥单抗）等产品强劲驱动。其中，靶向CD38的多发性骨髓瘤治疗药物Darzalex在全球所有地区的市场份额持续增长，全年收入达116.70亿美元，同比增长19.8%。这是该药自2015年上市以来，销售额首次突破100亿美元大关。多发性骨髓瘤是强生重点布局的疾病领域，CD38单抗Darzalex之外，BCMA CAR-T细胞疗法Carvykti（与传奇生物合作开发）、CD3/BCMA双抗Tecvayli、CD3/GPRC5D双抗Talvey（talquetamab，皮下注射制剂）均取得不俗表现。 Carvykti凭借着92.7%的增长速度一马当先，成为了强生2024年创新制药业务中增长最为迅猛的产品，其全年销售额达9.63亿美元，比去年翻了近1倍。2024年4月，FDA基于CARTUDE-4研究结果，批准该药用于多发性骨髓瘤的二线治疗，这是Carvykti获批的第二个适应症。随着适应症的扩大及产能提升，该药未来还具有很大增长空间。此外，强生的双抗TCE Tecvayli销售额达5.49亿美元，同比增长38.8%。另一款双抗TCE Talvey上市一年，尽管未披露具体销售额，但也将持续扩大强生在多发性骨髓瘤领域的竞争优势。强生血液瘤另一重磅产品Imbruvica（伊布替尼）因面临激烈的竞争压力，2024年的销售额同比下降6.9%，为30.38亿美元。前列腺癌重磅产品Zytiga（阿比特龙）因专利到期，销售额同样严重下滑，为6.31亿美元（-28.8%）。不过雄激素受体抑制剂Erleada（阿帕他胺）已接棒Zytiga，成为强生在该领域的核心产品。该药自2018年上市以来，以每年两位数或更高的增长率，迅速占领市场份额，2024年全年收入达29.99亿美元（+25.6%）。为保持在该领域的领先优势，强生还在2023年推出了阿比特龙+尼拉帕利复方制剂Akeega。 2024年，强生在非小细胞肺癌（NSCLC）领域也迎来了重大突破，其EGFR/c-Met双抗Rybrevant（埃万妥单抗）和EGFR T790M抑制剂Lazcluze（兰泽替尼）重磅产品组合获FDA批准，成为了EGFR 19号外显子缺失（ex19del）或L858R突变NSCLC患者的一线无化疗治疗方案。Rybrevant与化疗联用方案还被FDA批准用于EGFR 20号外显子插入突变NSCLC一线治疗、EGFR ex19del或L858R突变NSCLC二线治疗。这将推动强生肿瘤业务的进一步扩张。强生预测Rybrevant/Lazcluze产品组合销售峰值将突破50亿美元。在自身免疫领域，强生的销售业绩有所下滑，这主要是因为大单品Stelara（乌司奴单抗）受到生物类似药的冲击，收入同比下降了4.6%，为103.61亿美元，其欧洲市场已持续被侵蚀，预计2025年美国市场也将迎来生物类似药带来的巨大挑战。Remicade（英夫利西单抗）也因专利到期导致销售额连续下跌，2024年其全年收入为16.05亿美元，同比下降12.8%。Simponi（戈利木单抗）销售额为也略微下滑（-0.3%），为21.90亿美元。 Tremfya（古塞奇尤单抗）则继续保持着两位数的增长，2024年的销售额达到了36.70亿美元（+16.6%）。为了应对自免领域的危机，强生一方面挖掘已上市产品Tremfya的更多潜力，开展了多项该药治疗克罗恩病、溃疡性结肠炎、银屑病关节炎等疾病的III期临床研究，以拓展其适应症范围。另一方面，强生正在加速FcRn单抗nipocalimab、口服IL-23R拮抗剂JNJ-2113、组合抗体疗法JNJ-4804等候选药物的研发进程。2024年11月，JNJ-2113治疗斑块状银屑病的两项III期研究告捷，成为首款成功完成III期研究的口服IL-23R靶向药物。可以预见，强生将积极推动这些新产品上市，以弥补Stelara、Remicade、Simponi等产品业绩下降带来的影响。神经科学领域，Spravato（艾司氯胺酮鼻喷雾剂）表现亮眼，销售额达10.77亿美元，同比增长56.4%，成为强生又一个“十亿美元分子”。近期FDA还批准了Spravato单药治疗难治性抑郁症的新适应症，这将成为该药又一个极具潜力的增长点。值得注意的是，强生近期还斥资146亿美元收购了Intra-Cellular，进一步加强神经科学领域布局。强生预测这次收购获得的口服抗精神病产品Caplyta（lumateperone）销售峰值有望突破50亿美元。 2024年，强生在肺动脉高压领域收入增长主要得益于Opsumit（马昔腾坦）和Uptravi（司来帕格），这两款药物销售额分别为21.84亿美元（+10.7%）、18.17亿美元（+14.9%）。这一年里，强生在生物制药并购交易方面也相对活跃，3月份，以20亿美元完成了对ADC公司Ambrx的收购，加强了肿瘤产品管线；6月份，以8.5亿美元完成了对双抗公司Proteologix的收购，获得多个针对特应性皮炎和哮喘的抗体项目；7月份，以12.5亿美元完成了对Yellow Jersey的收购，获得了一款靶向IL-4Rα和IL-31的first-in-class双抗NM26的全球权益，用于治疗特应性皮炎。 2024年，强生的创新制药产品管线在注册监管和重要临床研究数据读出方面也达成了多个关键的里程碑事件（详见下图）。展望2025年，强生预计会有2.5%-3.5%的增幅，总收入有望达到909-917亿美元。推荐阅读全球首个治疗“慢性排异”ROCK2抑制剂正式纳入医保报销 Copyright © 2025 PHARMCUBE. All Rights Reserved. 欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

免疫疗法细胞疗法财报专利到期上市批准

2025-01-22

·BioPharmaDive

J&J oncology sales grow, but shares slide on outlook

Dive Brief:Johnson & Johnson on Wednesday reported modestly higher-than-expected earnings for the fourth quarter, while cautioning that unfavorable currency exchange rates would temper sales growth this year.Adjusted earnings per share reached $2.04 in the fourth quarter, higher than the Wall Street consensus of $2.01 and Leerink Partners estimate of $1.96, Leerink analyst David Risinger wrote in a note to clients. The companys sales rose 5.3% to $22.5 billion during the quarter, in line with estimatesFull-year 2024 revenue increased to $88.8 billion from $85.2 billion in 2023. For this year, J&J expects revenue to climb to between $89.2 billion and $90 billion, with a mid-point of $89.6 billion, less than the consensus estimate of $91.1 billion. Shares of the company dropped about 3% in early trading Wednesday, even as the overall market rose.Dive Insight:CEO Joaquin Duato is looking to newer medicines to drive J&Js sales growth as the company fights through generic competition for its second-best selling drug, Stelara. Worldwide sales of Stelara dropped 15% to $2.3 billion in the fourth quarter, with most of the decline coming from overseas, where copycat competition already has a toehold. In the U.S., Amgen recently launched the first biosimilar of Stelara and more are on the way.Even so, J&J is poised for sustained growth through this decade, Duato said. I cannot think of any other company that would be able to deliver growth through the first year of losing exclusivity of a multibillion-dollar product, Duato told analysts on a conference call.That growth will depend in large part on the continued success of the companys cancer medicines, led by Darzalex. Sales of the drug jumped 21% to $3.1 billion in the fourth quarter. At the same time, J&Js Carvykti, a CAR-T treatment for multiple myeloma, came close to breaking $1 billion in sales for the year. J&J will also be looking for growth from newer medicines including Tecvayli and Talvey.Outside of oncology, J&Js depression treatment Spravato brought in sales of $1.1 billion for the year, a 56% increase from the previous year. And the drug will benefit in 2025 from an expanded Food and Drug Administration approval in people with treatment-resistant depression.J&J also plans to expand its psychiatric offerings with the $14.6 billion acquisition of Intra-Cellular Therapies announced last week. Intra-Cellular sells a drug called Caplyta for schizophrenia and bipolar disorder and is looking to expand its use for patients with major depressive disorder. '

并购细胞疗法

100 项与塔奎妥单抗相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
多发性骨髓瘤	美国	Janssen Biotech, Inc.	2023-08-09

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性多发性骨髓瘤	临床3期	美国	Janssen Research & Development LLC	2022-10-20
难治性多发性骨髓瘤	临床3期	波兰	Janssen Research & Development LLC	2022-10-20
外周干细胞移植	临床2期	美国	Janssen Scientific Affairs LLC	2025-11-01
阴燃多发性骨髓瘤	临床2期	美国	Janssen Scientific Affairs LLC	2023-12-04
复发性多发性骨髓瘤	临床2期	美国	Janssen Research & Development LLC	2021-02-01
复发性多发性骨髓瘤	临床2期	中国	Janssen Research & Development LLC	2021-02-01
复发性多发性骨髓瘤	临床2期	日本	Janssen Research & Development LLC	2021-02-01
复发性多发性骨髓瘤	临床2期	比利时	Janssen Research & Development LLC	2021-02-01
复发性多发性骨髓瘤	临床2期	法国	Janssen Research & Development LLC	2021-02-01
复发性多发性骨髓瘤	临床2期	德国	Janssen Research & Development LLC	2021-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04586426 (RedirecTT-1, Pubmed) 人工标引	临床1/2期	多发性骨髓瘤 \| 难治性多发性骨髓瘤	94	Talquetamab + Teclistamab	鏇醖簾簾艱顧憲顧簾簾(鹽淵壓糧繭鹹鑰構遞鑰) = 憲範築築製顧艱網鹹襯獵鬱淵齋鹹網廠窪壓憲 (夢衊積淵鏇鹹衊築襯繭 ) 更多	积极	2025-01-09
				Talquetamab 0.8 mg/kgTalquetamab 0.8 mg/kg + Teclistamab 3.0 mg/kgTeclistamab 3.0 mg/kg (RP2R)	網糧襯淵積膚鏇壓觸鏇(淵壓膚夢窪範製窪鹹網) = 蓋遞醖廠鹽選艱積繭鑰觸獵願夢夢壓膚憲築廠 (餘齋衊餘範觸顧製鏇蓋 ) 更多
NCT04586426 (RedirecTT-1, Pubmed \| N Engl J Med)	临床1/2期	难治性多发性骨髓瘤	94	Talquetamab 0.8 mg/kg + Teclistamab 3.0 mg/kg	鹹觸繭壓艱淵襯選憲繭(衊繭夢膚鹹夢簾願齋網) = 襯憲選襯網夢淵壓窪繭築醖衊餘願築製齋繭顧 (鬱襯觸廠糧鏇憲憲襯選 ) 更多	积极	2025-01-09
ASH2024	N/A	难治性多发性骨髓瘤	-	Talquetamab 0.4 mg/kg weekly	齋顧遞餘選衊窪廠衊餘(觸壓憲觸糧襯願遞艱鏇) = 選繭鑰鹽艱襯築鏇鏇積範鹽艱願壓襯獵淵廠壓 (製餘糧淵遞鏇簾醖廠憲 ) 更多	-	2024-12-08
				Talquetamab 0.8 mg/kg every other week	齋顧遞餘選衊窪廠衊餘(觸壓憲觸糧襯願遞艱鏇) = 簾構構壓膚網繭鬱觸衊範鹽艱願壓襯獵淵廠壓 (製餘糧淵遞鏇簾醖廠憲 ) 更多
ASH2024	N/A	多发性骨髓瘤	-	Talquetamab 0.6 mg/kg Q2W	構蓋獵鹹願襯範淵艱淵(鑰鏇鏇糧製觸糧顧築願) = Cytokine release syndrome (CRS) were graded by American Society of Transplantation and Cellular Therapy criteria; all other adverse events (AEs) were graded by Common Terminology Criteria for Adverse Events v5.0. 淵鏇築選築觸鹹壓夢遞 (築構蓋窪繭醖壓壓壓獵 ) 更多	-	2024-12-07
				Talquetamab 0.8 mg/kg Q4W
SOHO2024	N/A	多发性骨髓瘤	-	Talquetamab 0.4 mg/kg QW	鏇選襯餘築窪夢蓋鹹鬱(餘簾齋蓋鑰醖廠窪艱構) = 74.3% (most grade 1/2, 1 grade 3) 鹹鑰夢觸願艱願夢衊膚 (蓋艱衊獵鏇築繭淵憲餘 ) 更多	-	2024-09-04
				Talquetamab 0.8 mg/kg Q2W
NCT03399799 \| NCT04634552 (MonumenTAL-1, SOHO2024)	临床1/2期	多发性骨髓瘤 GPRC5D \| CD3	375	Talquetamab 0.4 mg/kg QW	繭簾築鏇獵衊糧廠簾艱(鹹鹹壓膚艱鹹顧鬱顧夢) = Early onset of GPRC5Drelated AEs was associated with a higher likelihood of response 鏇餘鏇遞糧築遞窪繭獵 (遞鏇繭廠窪廠選夢憲願 ) 更多	积极	2024-09-04
				Talquetamab 0.8 mg/kg Q2W
NCT03399799 \| NCT04634552 (MonumenTAL-1, ASCO2024) 人工标引	N/A	多发性骨髓瘤	21	Talquetamab	積壓顧鏇廠鏇鏇蓋積衊(廠窪壓衊鑰糧遞網夢衊) = 鑰獵蓋觸顧夢遞鑰襯壓襯餘壓廠蓋構構餘鏇鏇 (構窪網憲鹽鹽糧艱壓鬱 ) 更多	积极	2024-05-24
ASCO2024	N/A	多发性骨髓瘤	-	Talquetamab	餘願蓋鏇齋選齋構簾觸(製醖餘衊壓夢蓋糧製範) = Cytokine release syndrome occurred in 12 patients (70.6%), with 5 patients (29.4%) in grade 2 or higher CRS 艱願艱鬱蓋醖醖齋簾鑰 (廠網夢壓糧衊齋襯艱鏇 ) 更多	-	2024-05-24
NCT05050097 (MonumenTAL-2, EHA 12024 \| EHA 22024) 人工标引	临床1期	多发性骨髓瘤三线	35	Talquetamab 0.4 mg/kg weekly	膚願選繭醖窪齋獵壓鏇(顧醖鬱鏇製範襯鏇夢積) = Grade 3/4 AEs occurred in 91.4% of pts 壓網夢糧願繭鬱鑰積簾 (製膚選餘願齋構選遞選 )	积极	2024-05-14
				Talquetamab 0.8 mg/kg every other week
NCT03399799 \| NCT04634552 (MonumenTAL-1, EHA2024) 人工标引	临床1/2期	多发性骨髓瘤末线	29	Talquetamab 0.4 mg/kg QW	鏇醖願糧構壓鬱網製願(築壓繭窪鑰憲選築壓壓) = 襯築艱積顧獵膚醖遞築構築觸鹹壓選網鬱襯鹹 (衊鏇襯顧積淵願鑰窪糧 ) 更多	积极	2024-05-14